{Reference Type}: Journal Article
{Title}: Micropulse transscleral cyclophotocoagulation (MP-CPC): efficacy endpoints for the treatment of refractory paediatric glaucoma - a retrospective case-series.
{Author}: Balbaid N;AlJodai M;Fairaq G;AlEnzi M;AlShahwan S;
{Journal}: BMC Ophthalmol
{Volume}: 24
{Issue}: 1
{Year}: 2024 Feb 28
{Factor}: 2.086
{DOI}: 10.1186/s12886-024-03358-0
{Abstract}: <B>BACKGROUND: </B>This study evaluates the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-CPC) in paediatric patients.<BR><B>METHODS: </B>This retrospective case-series recruited 44 eyes for glaucoma patients who were younger than 17 years and were treated with MP-CPC and followed for at least one year. Pre- and post-intervention intraocular pressure (IOP) was compared out to at least one year postoperatively. Success rates at 6 months and 1 year postoperatively were assessed. P < 0.05 was considered statistically significant.<BR><B>RESULTS: </B>There were 35 (79.5%) eyes with a history of glaucoma surgery. IOP decreased statistically significantly from a baseline of 32.7 (standard deviation:8.7 mmHg) to 23.2 (8.6) and 21.7 (7.9) mmHg at the 6 months and 1-year follow-up, respectively (P < 0.0001, all comparisons). Overall success was noted in 19 (47.5%) eyes at the 6 months follow-up, and 23 (53.5%) eyes at 1 year.<BR><B>CONCLUSIONS: </B>MP-CPC reduces IOP and the burden of medications in paediatric patients with glaucoma. Additionally, its safety profile favours the use of MP-CPC as an adjunctive modality for refractory glaucoma.